Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
lutikizumab + ABBV-295
- Development stage
- Preclinical
- Lead developer
- AbbVie
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Peptides
- Administration
- Subcutaneous
01
Overview
lutikizumab + ABBV-295 is an investigational combination therapy being developed by AbbVie for the treatment of moderate to severe hidradenitis suppurativa (HS). The combination pairs lutikizumab (ABT-981), a dual-variable-domain immunoglobulin (DVD-Ig) that simultaneously targets and inhibits interleukin-1 alpha (IL-1α) and interleukin-1 beta (IL-1β), with ABBV-295 (GUB014295), a long-acting amylin analog originally discovered by Gubra. The therapeutic rationale is that obesity is a major risk factor and exacerbating factor in HS; thus, combining the anti-inflammatory effects of lutikizumab with the weight-reduction benefits of ABBV-295 may provide synergistic efficacy. AbbVie plans to evaluate this combination in an HS platform study starting in late 2026.
- Other names
- ABT-981 + ABBV-295ABT-981 + GUB014295lutikizumab + GUB014295
02
Targets
AMY receptor (Calcitonin receptor (with ramps))CALCR (Calcitonin receptor)IL1A (Interleukin 1 alpha)IL1B (Interleukin-1 beta)
Beyond the preview
Go deeper on lutikizumab + ABBV-295.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on lutikizumab + ABBV-295.